Clinical and Molecular Prognostic Factors for Long-Term Survival of Patients with Glioblastomas in Single-Institutional Consecutive Cohort

Nakagawa, Yu; Sasaki, Hidenao; Ohara, Kentaro; Ezaki, Taketo; Toda, Masahiro; Ohira, Takayuki; Kawase, Takeshi; Yoshida, Kazunari

doi:10.1016/j.wneu.2017.06.126

Cited by 32 publications

(22 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The low survival rate in patients younger than 50 years is somewhat conflicting and probably due to the low number of patients. The youngest patients among 2‐year survivors all had unmethylated MGMT, indicating young age as an important prognostic factor, as shown in other studies . The median survival in our county before the implementation of Stupp was shorter (7.7 months) than for the group treated with surgery and radiotherapy alone (12.1 months) in the original Stupp study, indicating poor treatment response between 2001 and 2005.…”

Section: Discussionsupporting

confidence: 68%

Improved survival of Swedish glioblastoma patients treated according to Stupp

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 68%

Improved survival of Swedish glioblastoma patients treated according to Stupp

et al. 2018

View full text Add to dashboard Cite

show abstract

“…This translates into a clinical effect – survival of patients with methylated MGMT promoter treated with TMZ was significantly higher (21.7 months) compared with patients with non-methylated MGMT (15.3 months) [ 27 ]. Interestingly, MGMT promoter methylation was statistically significantly related to survival over 3 years, but was no longer significant in patients who survived 5 years or more [ 28 ]. Surprisingly, MGMT gene methylation is prognostic but not predictive of response to TMZ chemotherapy in anaplastic glioma [ 29 ].…”

Section: Methylation Of the Mgmt Gene Promotermentioning

confidence: 99%

Clinical and immunological correlates of long term survival in glioblastoma

Czapski¹,

Baluszek²,

Herold‐Mende³

et al. 2018

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most common and most aggressive type of primary brain tumour in adults. It represents 54% of all gliomas and 16% of all brain tumours (Ostrom et al. 2016). Despite surgery and treatment with radiotherapy plus an oral alkylating agent, temozolomide (TMZ), tumours invariably recur, and the patient survival is an average of ~14–16 months. In this review we summarise the current understanding of multiple factors that may affect survival of patients with GBMs. In particular, we discuss recent advancements in surgery and detection of genomic-based markers with prognostic values, such as IDH1/2 mutations, MGMT gene promoter methylation, and TERT gene promoter alterations. We address the issue of tumour heterogeneity and evolution that may result in different parts of the same tumour exhibiting different GBM subtypes and in subtype switching, which may restrict the usefulness of the expression-based classification as a prognostic marker before relapse. The determinants of long-term survival in patients with IDH1/2wt GBM, beyond MGMT promoter methylation, remain to be identified, and even the absence of both IDH1/2 mutations and MGMT promoter methylation does not preclude long-term survival. These findings suggest that host-derived factors, such as immune system responsiveness may contribute to long-term survival in such patients. We report the results of high-throughput approaches, suggesting links between long-term survival and enhanced immune-related gene expression. The further search for new gene candidates, promoter methylation status, and specific features of host immunity should provide prognostic biomarkers for the evaluation of survival of IDH1 wild-type/non-G-CIMP GBMs.

show abstract

“…Clinical factors such as age at presentation, tumour location, Karnofsky performance status, extent of surgery and isocitrate dehydrogenase (IDH) status are well-known prognostic factors for GBM (4). Identification of more accessible and cost-effective prognostic factors may better guide adjuvant treatment decisions.…”

Section: Introductionmentioning

confidence: 99%

Prognostic significance of pre‑treatment neutrophil‑to‑lymphocyte ratio and platelet‑to‑lymphocyte ratio in patients with glioblastoma

et al. 2018

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumour in adults. Identification of accessible and cost-effective prognostic factors may better guide adjuvant treatment-related decisions. The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are markers of host inflammatory response, and their increase has recently been shown to be a poor prognostic factor in several malignancies. The aim of the present study was to investigate the prognostic value of preoperative NLR and PLR in GBM patients. Between 2012 and 2017, 104 patients who had undergone surgery for GBM were considered for adjuvant therapy in our institution. Of those, 80 patients with evaluable pre-corticosteroid full blood count results were identified and included in the final analysis. The Eastern Cooperative Oncology Group performance status, localization, radiochemotherapy and second-line systemic therapy were found to be independent prognostic indicators for progression-free and overall survival. The median overall survival was 13.2 months. Patients with NLR <4 had a better median overall survival of 10.7 vs. 7.8 months in patients with NLR >4; however, this difference was not statistically significant (P>0.05). Overall survival also did not differ significantly between patients with low and those with high PLR values (10.2 vs. 15.2 months, respectively; P=0.105). In conclusion, the results of the present study suggest that pre-treatment NLR and PLR do not have prognostic value in GBM patients; however, large-scale trials are required to confirm these findings.

show abstract

Clinical and Molecular Prognostic Factors for Long-Term Survival of Patients with Glioblastomas in Single-Institutional Consecutive Cohort

Cited by 32 publications

References 23 publications

Improved survival of Swedish glioblastoma patients treated according to Stupp

Improved survival of Swedish glioblastoma patients treated according to Stupp

Clinical and immunological correlates of long term survival in glioblastoma

Prognostic significance of pre‑treatment neutrophil‑to‑lymphocyte ratio and platelet‑to‑lymphocyte ratio in patients with glioblastoma

Contact Info

Product

Resources

About